-
2024-09-11
Nuance Pharma completes recruitment for ENHANCE-CHINA, the phase 3 clinical trial of ensifentrine for the maintenance treatment of COPD
Nuance Pharma announced it has completed the recruitment of patients for the ENHANCE-CHINA study, after planned number of patients have been successfully enrolled.
-
2024-08-14
PharmaBoardroom Interview with Nuance Pharma founder & CEO Mark Lotter
From a demographic and disease profile perspective, Asia-Pacific shares more similarities with China than with Western markets. This alignment makes expanding into Asia-Pacific a logical step.
-
2024-06-27
US FDA New Drug Application Approval of Ohtuvayre™ (ensifentrine) for the Maintenance Treatment of COPD
Nuance Pharma's global partner Verona Pharma plc (Nasdaq: VRNA), announces the US Food and Drug Administration ("FDA") approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patie
-
2024-06-27
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
Verona Pharma plc (Nasdaq: VRNA) announces the US Food and Drug Administration (“FDA”) approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
-
2024-03-12
Nuance Pharma Attended The 3rd BioCentury-BayHelix East-West Biopharma Summit in Singapore
- 1
Contact PR
